INTRODUCTION
Endotoxin tolerance is defined as a reduced responsiveness to a lipopolysaccharide (LPS) challenge following a first encounter with endotoxin. Endotoxin tolerance has been also named deactivation, adaptation, desensitization, anergy, refractoriness or reprogrammation. In many aspects it resembles the immunodepression/immunosuppression/ immunoparalysis which has been reported in patients with sepsis or non-infectious systemic inflammatory response syndrome (SIRS) such as trauma, surgery, cardiopulmonary bypass, cardiac arrest and resuscitation, and hemorrhagic shock. Numerous, although not all, LPS-induced activities are altered as a consequence of endotoxin tolerance. Various aspects of endotoxin tolerance not addressed in this text can be found in the recent review by Cross. 1 
Endotoxin tolerance and fever
Beeson first reported endotoxin tolerance in 1946 2 as the abolition of the fever response of rabbits undergoing repeated daily injection of the same dose of typhoid vaccine. It was later shown that plasma of a tolerant rabbit could passively transfer tolerance to pyrogenicity of bacterial endotoxin in another. 3 In human volunteers, it was shown that inoculation of live Salmonella typhosa led to a reduced fever in response to endotoxin or killed bacteria as compared to before infection. 4 Interestingly, a similar observation was reported with volunteers inoculated with Plasmodium cynomolgi by mosquito bites, 5 suggesting that cross-tolerization between different stimuli could occur Beeson (1946) first defined endotoxin tolerance as a reduced endotoxin-induced fever following repeated injections of typhoid vaccine. Freudenberg and Galanos (1988) demonstrated that endotoxin tolerance that can protect against a lethal challenge of lipopolysaccharide (LPS) involves the participation of macrophages. Evans and Zuckerman (1991) reported a role for glucocorticoids in endotoxin tolerance. Prostaglandins, interleukin-(IL-)10, and transforming growth factor-b are other players of in vivo endotoxin tolerance. Dramatic reduction of plasma tumor necrosis factor (TNF) (Mathison et al. 1990 ) and other cytokines in response to LPS parallels endotoxin tolerance. The reduced capacity to produce TNF and other cytokines can be mimicked in vitro by pretreatment of monocytes or macrophages with LPS. It is not a specific phenomenon and can be induced by other agents or events. Cross-tolerance between LPS, TLR2 specific ligands, IL-1 and TNF has been regularly reported. A similar loss of LPS-reactivity has been repeatedly reported in leukocytes of septic patients and in patients with non-infectious systemic inflammation response syndrome (SIRS; e.g. surgery, trauma, cardiac arrest and resuscitation, etc.). Studies on cellular signaling within leukocytes from septic and SIRS patients reveal numerous alterations of the activation pathways reminiscent of those observed in endotoxin-tolerant cells. While endotoxin tolerance prevents severity of infections and ischemia-reperfusion damage, it has been suggested that the immune dysregulation observed in SIRS patients was associated with an enhanced sensitivity to nosocomial infections. In conclusion, in vitro and in vivo endotoxin tolerance, either experimental or due to clinical status, are similar but not identical.
(cross-tolerization will be addressed later). In addition to human volunteers, reduced fever to endotoxin or killed bacteria was reported in different infections such as in patients with pyelonephritis, 6 in patients convalescent from typhoid and paratyphoid fever, 7 and in patients recovering from malaria. 8 
Endotoxin tolerance and resistance to LPS-induced shock
Not only can pretreatment with endotoxin reduce subsequent LPS-induced fever in rabbits, but it also prevents LPS-induced lethality. 9 In mice, even when LPS-induced lethality is dramatically enhanced by galactosamine treatment, LPS tolerization can prevent LPS-induced mortality. 10 
Endotoxin tolerance and resistance to inflammatory process
It is worth recalling that endotoxin tolerance has been associated with increased resistance and protection against tissue injuries and even mortality in models such as infected thermal injury, 11 hepatic ischemia/reperfusion, 12 renal ischemia/reperfusion, 13 coronary occlusion, 14 or hemorrhagic shock. 15 All these increased resistances to stressful situations further illustrate that endotoxin tolerance is far more than a single altered inflammatory responsiveness to only LPS.
Endotoxin tolerance and resistance to infection
Some studies suggested that the induction of endotoxin tolerance might impair resistance to infectious processes. For example, a reduced level of interferon was reported in animals pretreated with LPS and further challenged with Newcastle disease virus. 16 In addition, a reduced leishmanicidal activity was observed after preexposure of macrophages to LPS, 17 and an impaired lung clearance of Pseudomonas aeruginosa was shown after LPS exposure. 18 However, more recently, the analysis of infectious models using either Cryptococcus neoformans 19 or Salmonella enterica 20 established that mice rendered tolerant to LPS had an increased resistance to fungal and bacterial infections, associated with a reduced burden of pathogens within the tissues. Most likely, as suggested by experiments combining pentoxifylline and LPS-pretreatment, 19 one can postulate that the boost of tumor necrosis factor (TNF), among other cytokines, during the first stimulation by LPS, later increased the resistance of the animals to the infectious process, as regularly demonstrated when the protective role of inflammatory cytokines was first established in the 1980s. Accordingly, it is difficult to assume that the increased susceptibility of SIRS patients to nosocomial infections is directly linked to the alteration of the reactivity of the immune cells that partially mimic the endotoxin tolerance.
ENDOTOXIN TOLERANCE AND CYTOKINE PRODUCTION
In vivo models TNF is most probably the best marker of endotoxin tolerance as assessed by its absence following an LPS challenge in tolerized animals, in contrast to its sharp and fast peak in response to a first injection of LPS. 21 Interestingly, not all cytokines behave similarly. We showed in a mouse model of tolerance, that, in addition to TNF, interleukin (IL)-6 and interferon-gamma (IFNg) released in the circulation following an LPS challenge were dramatically blunted, whereas this was not the case with IL-12p70, and the chemokines KC and MCP-1, the circulating levels of which were reduced but not as much as the previously mentioned cytokines. 22 Finally, in contrast, levels of IL-1b and IL-18 were maintained independently of the tolerization process. In humans, induction of tolerance by monophosphoryl lipid A led to a reduction of circulating TNF, IL-6 and IL-8 in response to a subsequent LPS challenge. 23 
In vitro models
Pre-treatment with LPS of macrophage cell lines 24, 25 as well as freshly isolated macrophages and monocytes 26 rendered the cells hyporeactive to a second LPS stimulus, particularly in terms of cytokine production. The phenomenon is dose dependent: the hyporeactivity of the cells to an LPS challenge is more severe after a pretreatment with the highest amounts of LPS.
Sepsis and systemic inflammatory response syndrome (SIRS)

Monocytes
An altered responsiveness of circulating human monocytes has been regularly reported in sepsis patients. IL1a, IL-1b, IL-6, and TNF production in ex vivo activation of patients' monocytes were significantly reduced upon LPS stimulation. 27 . Normal reactivity was never restored in non-surviving patients in contrast to those who recovered. This reduced responsiveness has also been reported for IL-12 and IL-10 but not for IL-1 receptor antagonist (IL-1ra).
28-30 Such a phenomenon has been reproduced in human volunteers receiving an injection of LPS. 31 
Neutrophils
McCall et al. 32 reported that circulating neutrophils from patients with sepsis showed a reduced capacity to respond in vitro to an LPS stimulation in terms of IL-1b production and considered that it corresponded to the endotoxin-tolerance phenomenon. More recently, we extended these findings to IL-8 and IL-1ra production and also reported the same phenomenon in non-infectious SIRS patients. 33, 34 However, we showed that, in contrast to human monocytes, human blood neutrophils from healthy controls could not be tolerized in vitro. Instead, pretreatment with LPS rendered the cells more reactive in terms of IL-8 production in response to a second stimulation with LPS.
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THE ACTORS OF ENDOTOXIN TOLERANCE
Adrenals and glucocorticoids
Evans and Zuckerman 35 induced endotoxin tolerance in normal and adrenalectomized mice. They showed that 18 h after a first injection of LPS, a peak of plasma TNF in adrenalectomized mice followed a second challenge of endotoxin, whereas no TNF could be detected in normal mice. However, injection of dexamethasone could not mimic the induction of tolerance by LPS. Their observation suggested that both glucocorticoid-dependent and independent mechanisms were involved in endotoxin tolerance. Whether glucocorticoids are involved in the immunodepression observed in sepsis remains an open question. It may depend upon the patients since Annane et al. 36 reported that one-third of septic shock patients had high levels of basal cortisol while more than half of patients had adrenal insufficiency as assessed by a reduced response to corticotropin. It is worth noting that both high levels of basal cortisol and reduced cortisol production upon triggering were associated with poor outcome.
Macrophages
Freudenberg and Galanos 10 elegantly demonstrated the role of macrophages in induction of endotoxin tolerance. Using C3H/HeJ low-responder mice, they showed that transfer of macrophages from C3H/HeN LPS responder mice allowed the induction of endotoxin tolerance.
Cytokines
In vitro tolerization of human monocytes could be partially mimicked by IL-1, IL-10 and TGFb, 37 and the use of anti-IL-10 and anti-TGFb antibodies during the step of tolerization could prevent the phenomenon. 29 However, in vivo tolerization could be achieved in IL-10 deficient mice, 38 and in septic patients the decreased ex vivo production of TNF and IL-6 could not be reversed by neutralization of IL-10. 39 Nevertheless, plasma of shock patients with meningococcemia revealed a strong LPS-inhibitory capacity that was abolished after removal of native IL-10 by immunoprecipitation. 40 These results led Brandzaeg et al. 40 to consider IL-10 as a major functional de-activator of human monocytes. However, we demonstrated that IL-10 was not sufficient to explain the observed dysregulation that occurs in septic patients. 41 
Specific LPS-targeting inhibitors
We recently identified a further complexity of the plasma inhibitory properties. 42 We performed plasma exchange experiments in order to determine whether the hyporeactivity observed for leukocytes from SIRS patients could be reversed by incubation with plasma from healthy controls, and also to test the capacity of the plasma of SIRS patients to exert an inhibitory effect on cytokine production by leukocytes from healthy controls. The effect of experimental procedures itself on cellular reactivity was tested by mixing autologous cell pellets and plasma at the end of the washing steps; in all cases, the production of TNF was compared to that obtained with whole blood before separation. In resuscitated patients after cardiac arrest (CA), studied as a group of SIRS patients, almost no TNF was produced in the whole blood in response to LPS, whereas responsiveness to heat-killed Staphylococcus aureus Cowan I (SAC) stimulation was unaltered (Fig. 1) . The manipulation of the blood itself induced some alteration as assessed by the lower production of TNF in response to LPS by reconstituted blood from healthy controls. However, the cells were still reactive to LPS and produced detectable amounts of TNF. In contrast, when the cells from healthy controls were incubated with plasma from CA patients, a strong inhibition of TNF production was observed. The levels of TNF were significantly lower than those obtained before blood fractionating and also lower than those from reconstituted autologous blood, suggesting that patients' plasmas contain inhibitory mediators. In addition, the hyporeactivity of leukocytes of CA patients revealed with LPS was not reversed when the cells were washed and incubated with plasma from healthy controls. In contrast, the various plasma and cellular exchanges did not significantly affect the SAC-induced TNF production. These results indicate that leukocyte hyporeactivity to LPS was an intrinsic defect that could not be reversed by normal plasma. More important, our data suggest that SIRS plasma which contains high levels of sCD14 43 and high levels of LPS-binding protein 44 may be particularly inhibitory towards the LPS-induced activation because of the presence of these molecules, of which high concentrations are known to inhibit LPS specifically. In addition, plasma lipoproteins are known to neutralize endotoxins, 45 and Warren et al. 46 have shown that LPS bound much more rapidly to lipoprotein fractions in tolerant serum than in normal serum. Altogether, these observations may partially explain why LPS responsiveness is specifically reduced as compared to other activators in certain SIRS patients.
REVERSAL OF ENDOTOXIN TOLERANCE
Reversal of endotoxin tolerance can be achieved in vitro with the use of IFN-g or granulocyte-macrophage colony stimulating factor (GM-CSF). Pretreatment of the Mono Mac 6 cell line with LPS and IFN-g failed to induce LPS tolerization in contrast to a pretreatment with LPS alone. 47 Interestingly, using human monocytes, Randow et al. 48 showed that IFN-g and GM-CSF were able to reverse the effect of a pretreatment with LPS. We recently demonstrated that these cytokines prevent endotoxin tolerance induced by low, but not by high, doses of LPS by inhibiting IRAK degradation and by promoting its association with MyD88 after a second LPS stimulation, which in turn led to NF-kB activation and TNF production. Furthermore, the prevention of tolerance by IFN-g and GM-CSF was independent of IRAK kinase activity. 49 Finally, in vivo, IFN-g and GM-CSF restore the systemic TNF response to LPS in endotoxin-tolerant mice. 50 In humans, subcutaneous injection of IFN-g in cancer patients reversed the reduction of serum levels of TNF, IL-6 and GM-CSF in response to a second challenge of LPS, but did not affect IL-8 levels. 51 An attempt to reverse monocyte deactivation in septic patients has been achieved with IFN-g. In vitro IFN-g pretreatment of peripheral blood mononuclear cells (PBMC) from septic patients led to an enhanced production of TNF in response to LPS. 52 In vivo treatment of patients with IFN-g, after admission in intensive care unit, led to a recovery of the capacity of the cells to respond to an ex vivo stimulation with LPS, while the expression of HLA-DR on the surface of monocytes (the low level being a marker of immune depression) was also restored.
THE NON-SPECIFIC NATURE OF ENDOTOXIN
TOLERANCE
Endotoxin tolerance has been considered for a long time to be specific to LPS, despite early observations which Effect of plasma exchange between resuscitated cardiac arrest (CA) patients (n = 7) and healthy ABO group compatible volunteers (controls; CTRL; n = 7) on the production of TNF in response to E. coli LPS (1 mg/ml) or heat-killed Staph. aureus Cowan I (SAC; 100 mg/ml). After blood collection, plasma and the cellular pellet were separated. Whole blood cultures were performed with unseparated blood (whole blood CA or CTRL), with reconstituted blood, i.e. washed cell pellet and plasma from the same person (CA cells + CA plasma or CTRL cells + CTRL plasma) and with mixed cells and plasmas (CA cells + CTRL plasma or CTRL cells + CA plasma). The final blood dilution was 1:5 in RPMI-1640 medium and the cultures were performed for 24 h at 37°C. TNF in the supernatants was assayed with a specific ELISA. Data are expressed as mean ± SE. *P < 0.05, **P < 0.005 when compared to whole blood from healthy controls, # P < 0.05 when compared to CTRL cells + CTRL plasma. Data were originally presented in Adrie et al.
suggested that is was not the case. For example, Greisman et al. 4 showed that a turpentine pretreatment of rabbits reduced by 70% the fever response to a further LPS challenge. Nowadays, cross-tolerization is well accepted and has been widely observed. We first reported that LPS-tolerized human monocytes were also hyporeactive, in terms of TNF production, to heat-killed Streptococcus pyogenes, Staphylococcus aureus and Zymosan. 37 More recently, a cross-tolerization was demonstrated between microbial compounds that activate cells via TLR4 such as LPS or TLR2 such as mycobacterial lipoarabinomannan, 53 fimbrillin from Porphyromonas gingivalis, 54 cholera toxin B, 55 or lipoteichoic acid from Gram-positive bacteria. 56 Monocytes from human volunteers receiving an injection of endotoxin were rendered hyporesponsive, not only to LPS but also to staphylococcal toxic shock syndrome toxin-1 (TSST-1). 31 We reported a similar hyporeactivity to LPS and TSST-1 in patients during aortic surgery. 57 In addition, a reduced responsiveness to another superantigen, staphylococcal enterotoxin B, and to LPS has been reported in septic shock. 58 Reduced ex vivo responsiveness to whole heat-killed Gram-positive bacteria such as Strep. pyogenes 59 and Staph. aureus 29, 60 has been also reported in severe sepsis. A similar hyporeactivity to LPS and Strep. pyogenes was observed in infectious and non-infectious SIRS. 33, 34 . In human volunteers receiving an injection of LPS, the responsiveness of neutrophils to Streptococcus pneumoniae was also significantly diminished. 61 In contrast, McCall et al. 32 showed an unaltered responsiveness of neutrophils from sepsis patients to Staph. aureus. Using whole blood assays, it was shown that patients with severe infection had suppressed TNF response to LPS concomitantly with unaltered response to Salmonella typhimurium and even enhanced response to Staph. aureus. 62 We also showed in trauma patients 63 and in patients resuscitated after cardiac arrest 42 that cytokine production was not diminished in response to heat-killed Gram-positive bacteria.
It is worth noting that cross-tolerization also occurs between endotoxin, TNF and IL-1. It was shown in vivo that repeated injections or infusion of TNF in rats could protect against a LD 50 injection of LPS, 64 suppress LPSinduced fever, 65 and cytokine production by bone marrow-derived adherent cells. 66 In addition, IL-1 was shown to be involved in the induction of endotoxin tolerance both in vivo 67 and in vitro. 37 However, studies on cellular signaling revealed that IL-1b induced cross-tolerance to LPS without suppressing LPS-induced activation of mitogen activated protein kinase (MAPK) or NF-kB. 68 Finally, injection of LPS in human volunteers rendered PBMC less reactive to IL-1. 31 Similarly, we recently reported that circulating leukocytes from trauma patients were less reactive to IL-1 and TNF in terms of IL-6 production.
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ENDOTOXIN TOLERANCE AND SIGNALING
Numerous analyses have been undertaken to understand the molecular mechanisms which underline the endotoxin tolerance phenomenon, from LPS receptor expression (including CD14 and TLR4) to downstream intracellular signaling. NF-kB is one of the main activating factors involved in pro-inflammatory cytokine production. Endotoxin tolerance has been associated with a decreased expression of NF-kB 69 and with a predominance of the inactive p50p50 heterodimer. 70 We demonstrated that a similar low expression of NF-kB and a enhanced level of the p50p50 heterodimer as compared to the active heterodimer p50p65 were found in sepsis 71 and in trauma. 72 Interestingly, not all pathways were altered as suggested by the work of Learn et al. 73 who showed that the LPS-inducible phosphatidylinositol 3-kinase-dependent signaling pathway that led to soluble IL-1ra release was fully functional in leukocytes from septic patients. Recently, we showed that the activation of p38 MAPK and Sp-1 transcription factor, involved in IL-10 production, was increased in PBMC from trauma patients after Escherichia coli LPS or heat-killed Staphylococci stimulation. Numerous other mediators of signal transduction are inhibited during endotoxin tolerance (e.g. ERK, SAPK, IRAK, MyD88) as reviewed by West and Heagy 74 but remain to be studied in SIRS patients.
